The Navigate Solution combines proprietary plate with disease-specific organoids to deliver a testing platform unlike anything else available in preclinical drug development. NaviPlate - our patented 384-well organoid system - integrates seamlessly with standard lab automation, making it immediately deployable within existing pharmaceutical workflows. The result: fast, reproducible, biologically meaningful data across the entire drug development pipeline, from early target discovery through to preclinical safety testing.
Our Solution
-
Our organoids are derived from human stem cells and engineered to mimic the architecture, function, and disease biology of real human tissue. This approach is actively endorsed by the FDA, NIH, EU, and UK regulatory bodies as the gold standard for next-generation preclinical testing - moving the industry beyond the limitations of animal models and static 2D cell culture.
-
NaviPlate's 384-well format enables the simultaneous testing of hundreds of drug candidates, doses, and conditions in a single run. Whether screening a compound library or validating a shortlist of targets, NaviPlate delivers the scale that modern drug discovery demands - without sacrificing biological complexity.
-
Compared to existing 3D preclinical models, NaviPlate dramatically reduces both turnaround time and cost per data point. Pharmaceutical and biotech teams can generate high-quality, decision-ready insights earlier in the pipeline - before expensive clinical investment is committed.
-
Standardised protocols and a controlled manufacturing process ensure that NaviPlate delivers consistent, comparable results across experiments, sites, and time points. In a field where variability has long undermined confidence in preclinical data, reproducibility is not a feature - it is a foundation.
What We Offer
Our applications are validated across disease areas where conventional preclinical models have the greatest limitations, and where human-relevant data is most urgently needed. Each application is purpose-built to solve a specific, high-value challenge in drug development.
-
We specialise in advanced kidney modelling for translational research and drug discovery. Our kidney models enable rigorous toxicity testing across proximal tubule cells and glomerular structures, delivering physiologically relevant, reliable data on compound effects at key sites of injury.
Powered by our proprietary NaviPlate 384-well platform, we support the high-throughput applications central to modern drug discovery - including mode of action studies, multi-readout profiling, and custom assay development for acute kidney injury, diabetic kidney disease, and chronic kidney disease. Our models give biotech and pharma teams the accuracy and scalability needed to advance drug screening and mechanistic studies with confidence.
-
Meaningful target discovery requires models that faithfully reflect human bone biology. NaviPlate is the only high-throughput 384-well bone-forming organoid platform available - integrating disease-specific organoids with CRISPR-edited stem cells to simultaneously capture both mineralisation and proliferation data, enabling large-scale screening, accelerating target identification, and de-risking preclinical decision-making. Where conventional models fall short on scale and biological fidelity, NaviPlate delivers both.
-
We are extending our platform into cardiac fibrosis and cardiotoxicity screening, two areas of critical unmet need in drug safety and cardiovascular drug development. Further details coming soon.
Working in one of these disease areas?
We partner with pharmaceutical and biotech teams to design studies, validate targets, and generate the data that moves programmes forward.